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Summary
 
Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to can-
cer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The
DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tetanus toxoid or tuber-
culin. 11 far advanced stage IV melanoma patients, who were progressive despite standard che-
motherapy, received five DC vaccinations at 14-d intervals. The first three vaccinations were
administered into the skin, 3 
 
3
 
 10
 
6
 
 DCs each subcutaneously and intradermally, followed by
two intravenous injections of 6 
 
3
 
 10
 
6
 
 and 12 
 
3 
 
10
 
6
 
 DCs, respectively. Only minor (less than
or equal to grade II) side effects were observed. Immunity to the recall antigen was boosted.
Significant expansions of Mage-3A1–specific CD8
 
1
 
 cytotoxic T lymphocyte (CTL) precursors
were induced in 8/11 patients. Curiously, these immune responses often declined after the in-
travenous vaccinations. Regressions of individual metastases (skin, lymph node, lung, and liver)
were evident in 6/11 patients. Resolution of skin metastases in two of the patients was accom-
panied by erythema and CD8
 
1
 
 T cell infiltration, whereas nonregressing lesions lacked CD8
 
1
 
T cells as well as Mage-3 mRNA expression. This study proves the principle that DC “vac-
cines” can frequently expand tumor-specific CTLs and elicit regressions even in advanced can-
cer and, in addition, provides evidence for an active CD8
 
1
 
 CTL–tumor cell interaction in situ
as well as escape by lack of tumor antigen expression.
Key words: dendritic cells • vaccination • active immunotherapy • melanoma •
cytotoxic T lymphocytes
 
I
 
t is now established that the immune system has cells,
particularly CD8
 
1
 
 CTLs, that can recognize tumor anti-
gens and kill tumors (1, 2). Nevertheless, a major problem
is that these T cells are either not induced or only weakly
induced, i.e., the T cells are not evident in the systemic cir-
culation. One possibility is that there is inadequate tumor
antigen presentation by dendritic cells (DCs),
 
1
 
 “nature’s ad-
juvant” for eliciting T cell immunity (3). Another is that
tumor-reactive T cells are tolerized by the tumors (1, 4).
Melanoma provides a compelling setting in which to pur-
sue a current goal of cancer immunotherapy, the generation
of stronger tumor-specific T cell immunity, particularly
with CTLs (4). The majority of tumor antigens identified
so far are expressed by melanomas (2). Limited antimelanoma
CTL responses have been detected (5), and infusions of IL-2
expanded killer cells can lead to rejection of melanoma (6).
Conventional adjuvants promote antibody rather than
CTL responses. Therefore, several novel strategies are be-
ing explored to induce tumor-specific T cell immunity.
DC vaccination is one of these (3). Immature DCs capture
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; DCs, den-
dritic cells; DTH, delayed-type hypersensitivity; MCM, monocyte-con-
ditioned medium; RT, reverse transcriptase; TT, tetanus toxoid. 
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antigens but lack full T cell–stimulatory activity (7). In the
presence of appropriate stimuli, such as inflammatory cyto-
kines, the DCs mature. DCs upregulate T cell adhesion and
costimulatory molecules as well as select chemokine recep-
tors that guide DC migration into lymphoid organs for
priming of antigen-specific T cells. The use of DCs as adju-
vants is supported by many animal experiments with pri-
marily mature DCs (3, 8). These studies have shown that
the injection of tumor antigen–loaded DCs reliably induces
tumor-specific CTL responses, tumor resistance, and in
some cases, regression of metastases (3, 8). In the few pilot
trials reported so far for humans, 
 
immature
 
 DCs have been
employed (9–11). Scattered tumor responses are reported,
but evidence for the induction of tumor-specific CTLs by
DC vaccination has not been shown.
We have developed a technique to generate large num-
bers of homogenous populations of 
 
mature
 
 and stable DCs
from monocytes in the absence of nonhuman proteins (12,
13). We are now exploring the use of these DCs as vaccine
adjuvants in humans. Here we provide the proof of the prin-
ciple by demonstrating that three intracutaneous injections
of Mage-3A1 peptide–pulsed mature DCs reliably enhance
Mage-3A1–specific CD8
 
1
 
 and recall CD4
 
1
 
 T cell immunity
in heavily pretreated, progressive stage IV melanoma patients
with large tumor loads. Expansions of Mage-3A1–specific
CTL responses have not been previously detected after
Mage-3A1 peptide vaccination in less advanced melanoma
patients (14), underscoring the potent adjuvant properties
of DCs. As regressions of metastases also occurred upon
DC-mediated immunization and were accompanied by
CD8
 
1
 
 T cell infiltration, we propose that the induced
Mage-3A1–specific CTLs are active in vivo.
 
Materials and Methods
 
Patient Eligibility Criteria
 
Patients were eligible if they suffered from stage IV (i.e., distant
metastases) cutaneous malignant melanoma (1988 American Joint
Committee on Cancer/Union Internationale Contre Cancer
pTNM staging system) that was not curable by resection and was
progressive despite chemo(immuno)therapy. Further inclusion cri-
teria were an expected survival 
 
$
 
4 mo, Karnofsky index 
 
$
 
60%,
age 
 
$
 
18 yr, measurable disease, HLA-A1 positivity, expression of
Mage-3 gene shown by reverse transcriptase (RT)-PCR in at least
one excised metastasis, and no systemic chemo-, radio-, or im-
munotherapy within 4 wk (6 wk in the case of nitrosurea drugs)
preceding the first DC vaccination. A positive skin test to recall
antigens was 
 
not 
 
required. Important exclusion criteria were ac-
tive central nervous system (CNS) metastasis, any significant psychi-
atric abnormality, severely impaired organ function (hematological,
renal, liver), active autoimmune disease (except vitiligo), previous
splenectomy or radiation therapy to the spleen, organ allografts, evi-
dence for another active malignant neoplasm, pregnancy, lactation,
or participation (or intent to participate) in any other clinical trial.
Concomitant treatment (chemo- or immunotherapy, corticoster-
oids, investigational drugs, paramedical substances) was prohibited.
Palliative radiation or surgical therapy of selected metastases and cer-
tain medications (acetaminophen/paracetamol, nonsteroidal anti-
inflammatory drugs, opiates) to control symptoms were allowed.
 
Clinical Protocol and Study Design
 
The study was performed at the Departments of Dermatology
in Erlangen, Würzburg, and Mainz, Germany according to stan-
dards of Good Clinical Practice for Trials on Medicinal Products
in the European Community. The protocol was approved by the
Protocol Review Committee of the Ludwig Institute for Cancer
Research (New York, NY) and performed under supervision of
its Office of Clinical Trials Management as study LUD #97-001.
The protocol was also approved by the ethics committees of the
involved study centers.
The study design is shown in Table II. All patients gave writ-
ten informed consent before undergoing a screening evaluation
to determine their eligibility. Extensive clinical and laboratory as-
sessments were conducted at visits 1, 5, and 8 (Table II) and con-
sisted of a complete physical examination, staging procedures,
and standard laboratory values as well as special ones (pregnancy
test, free testosterone in males, autoantibody profile, and antibodies
to HIV-1/2, human T cell lymphotropic virus type I, hepatitis B
virus, and hepatitis C virus). Patients were hospitalized and exam-
ined the day before each vaccination and were monitored for
48 h after the DC injections. Adverse events and changes in labora-
tory values were graded on a scale derived from the Common
Toxicity Criteria of the National Cancer Institute, National Insti-
tutes of Health, Bethesda, MD.
 
Production of the DC Vaccine
 
During prestudy screening, we tested a small amount of fresh
blood to verify that appropriate numbers of mature DCs could be
generated from the patient’s monocytes (12). Sufficient DC num-
bers could be successfully generated in all patients, but in some pa-
tients the test generation revealed that TNF-
 
a
 
 had to be added to
assure full maturation. To avoid repetitive blood drawings, we per-
formed a single leukapheresis during visit 2 to generate DCs as de-
scribed (13). In short, PBMCs from the leukapheresis (
 
$
 
10
 
10
 
 nu-
cleated cells) were isolated on Lymphoprep™ (Nycomed Pharma)
and divided into three fractions. The first fraction of 10
 
9
 
 PBMCs
was cultured on bacteriological petri dishes (Cat. #1005; Falcon
Labware) coated with human Ig (100 
 
m
 
g/ml; Sandoglobin™; San-
doz GmbH) in complete RPMI 1640 medium (BioWhittaker)
supplemented with 20 
 
m
 
g/ml gentamicin (Refobacin 10; Merck),
2 mM glutamine (BioWhittaker), and 1% heat-inactivated human
plasma for 24 h to generate monocyte-conditioned medium
(MCM) for later use as the DC maturation stimulus. The second
fraction of 3 
 
3
 
 10
 
8
 
 PBMCs was used for the generation of DCs for
vaccination 1 and delayed-type hypersensitivity (DTH) test I. Ad-
herent monocytes were cultured in 1,000 U/ml GM-CSF (10 
 
3
 
10
 
7 
 
U/mg; Leukomax™; Novartis) and 800 U/ml IL-4 (purity
 
.
 
98%; 4.1 
 
3
 
 10
 
7
 
 U/mg in a bioassay using proliferation of human
IL-4R
 
1
 
 CTLL; CellGenix; expressed in 
 
Escherichia coli
 
 and pro-
duced under good laboratory practice conditions but verified for
good manufacturing practice [GMP] safety and purity criteria by
us) for 6 d, and then MCM was added to mature the DCs. MCM
was supplemented in patients 04, 06, 09, 11, and 12 with 10 ng/ml
GMP-rhu TNF-
 
a
 
 (purity 
 
.
 
99%; 5 
 
3 
 
10
 
7
 
 U/mg in a bioassay us-
ing murine L-M cells; a gift of Dr. G.R. Adolf, Boehringer Ingel-
heim Austria, Vienna, Austria) to assure full maturation of DCs.
Mature DCs were harvested on day 7. The third fraction of PBMCs
was frozen in aliquots and stored in the gas phase of liquid nitrogen
to generate DCs for later vaccinations and DTH tests.
DCs for vaccinations were pulsed with the Mage-3A1 peptide
(15) (EVDPIGHLY, synthesized at GMP quality by Clinalfa) as
tumor antigen, and as a recall antigen and positive control, tetanus
toxoid (TT) or tuberculin (if at visit 1 the DTH to TT in the 
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Multitest Merieux was 
 
.
 
10 mm; both purchased from the Bacte-
rial Vaccines Department of the Statens Serum Institute, Copen-
hagen, Denmark). The recall antigen was added at 10 
 
m
 
g/ml for
the last 24 h, and the Mage-3A1 peptide was added at 10 
 
m
 
M di-
rectly to the cultures for the last 8 h (if immunity to recall anti-
gens was strongly boosted, the dose of recall antigen was reduced
to 1.0 or 0.1 
 
m
 
g/ml or was omitted for the intravenous DC in-
jections to avoid a cytokine release syndrome). On day 7, mature
DCs were harvested, resuspended in complete medium, washed,
and pulsed once more with Mage-3A1 peptide (now at 30 
 
m
 
M)
for 60 min at 37
 
8
 
C. DCs were finally washed and resuspended in
PBS (GMP quality PBS; BioWhittaker) for injection. DCs to be
used for Mage-3A1 DTH tests were pulsed with Mage-3A1 (but
no recall antigen); DCs that served as negative control in the
DTH tests were not pulsed at all. An aliquot of the DCs to be
used for vaccinations was analyzed as described (13) to assure that
functionally active and mature DCs were generated. The features
of the DCs are described in Results. Release criteria were typical
morphology (
 
.
 
95% nonadherent veiled cells) and phenotype
(
 
.
 
95% HLA-DR
 
111
 
CD86
 
111
 
CD40
 
1
 
CD25
 
1
 
CD14
 
2 
 
and 
 
.
 
65%
homogenously CD83
 
11
 
).
 
Immunization Schedule
 
A total of five vaccinations (three into the skin followed by
two intravenously) with antigen-pulsed DCs were given at 14-d
intervals (Table II). This design was chosen to explore the toxic-
ity and efficacy of various routes in this trial. For vaccinations 1–3,
3 
 
3
 
 10
 
6
 
 DCs were given subcutaneously at two sites (1.5 
 
3
 
 10
 
6
 
DCs in 500 
 
m
 
l PBS per site) and 3 
 
3
 
 10
 
6
 
 intradermally at 10 sites
(3 
 
3
 
 10
 
5
 
 DCs in 100 
 
m
 
l PBS per site). The injection sites were
the ventromedial regions of the upper arms and the thighs close
to the regional lymph nodes and were rotated clockwise. Limbs
where draining lymph nodes had been removed and/or irradiated
were excluded. For intravenous vaccinations 4 and 5, a total of 6
and 12 
 
3
 
 10
 
6
 
 antigen-pulsed DCs (resuspended in 25 or 50 ml
PBS plus 1% autologous plasma) was administered over 5 and 10
min, respectively. Premedication with an antipyretic (500 mg acet-
aminophen/paracetamol p.o.) and an antihistamine (2.68 mg cle-
mastinhydrogenfumarat i.v.) was given 30 min before intravenous
DC vaccination.
 
Evaluation of Immune Status
 
Recall Antigen–specific Proliferation and Cytokine Production.
 
PBMCs were cultured in triplicate at two dose levels (3 
 
3
 
 10
 
4
 
and 1 
 
3 
 
10
 
5 
 
PBMCs/well) plus or minus TT or tuberculin (at
0.1, 1, and 10 
 
m
 
g/ml) and pulsed on day 5 with [
 
3
 
H]thymidine
for 12 h. In all cases, the highest cpms were obtained with the
highest doses of PBMCs and antigen and are shown in Fig. 2.
IL-4 and IFN-
 
g
 
 levels were measured in culture media by ELISA
(Endogen, Inc.). In a separate plate, staphylococcal enterotoxin
(SEA; Serva) was added at 0.5, 1, and 5 ng/ml, and proliferation
was assessed after 3 d to provide a positive control for helper T
cell viability and responsiveness.
 
Enzyme-linked Immunospot Assay for IFN-
 
g
 
 Release from Single
Antigen–specific T Cells.
 
To quantitate antigen-specific, IFN-
 
g
 
–
releasing, Mage-3A1–specific effector T cells, an enzyme-linked
immunospot (ELISPOT) assay was used as described (16). PBMCs
(10
 
5
 
 and 5 
 
3 
 
10
 
5
 
/well) or in some cases
 
 
 
CD8
 
1
 
 or CD4
 
1
 
 T cells
(isolated by MACS™ according to the manufacturer, Miltenyi
Biotec) were added in triplicate to nitrocellulose-bottomed 96-well
plates (MAHA S4510; Millipore Corp.) precoated with the pri-
mary anti–IFN-
 
g
 
 mAb (1-D1K; Mabtech) in 50 
 
m
 
l ELISPOT
medium (RPMI 1640 and 5% heat-inactivated human serum) per
well. For the detection of Mage-3A1–reactive T cells, the APCs
were irradiated T2.A1 cells (provided by P. van der Bruggen,
Ludwig Institute of Cancer Research, Brussels, Belgium) pulsed
with MHC class I–restricted peptides (Mage-3A1 peptide and the
HIV-1 p17-derived negative control peptide GSEELRSLY) added
at 7.5 
 
3
 
 10
 
4/well (final volume 100 ml/well). After incubation
for 20 h, wells were washed six times, incubated with biotiny-
lated second mAb to IFN-g (7-B6-1; Mabtech) for 2 h, washed,
and stained with Vectastain Elite kit (Vector Labs.). For detec-
tion of TT-reactive T cells, TT was added at 10 mg/ml directly to
the PBMCs (1 or 5 3 105 PBMCs/flat-bottomed 96-well plate).
Assays were performed on fresh PBMCs. Spots were evaluated
and counted using a special computer-assisted video imaging analy-
sis system (Carl Zeiss Vision) as described (16).
Semiquantitative Assessment of CTL Precursors. The multiple
microculture method developed by Romero et al. (17) was used
to obtain a semiquantitative assessment of CTLp (precursors) spe-
cific for Mage-3A1 peptide. Aliquots of frozen PMBCs were
thawed and assayed together. CD81 T cells were isolated with
magnetic microbeads (MACS™ separation columns; Miltenyi Bio-
tec) and seeded at 104/well in 96-well round-bottomed plates in
RPMI 1640 with 10% heat-inactivated human serum. The CD82
PBMCs were pulsed with peptide Mage-3A1 or the influenza
PB1 control peptide VSDGGPNLY (10 mg/ml; 30 min at room
temperature), irradiated (30 Gy from a cesium source), and added
as an APC population at 105/well together with IL-2 (10 IU/ml
final) and IL-7 (10 ng/ml final) in a total volume of 200 ml/well.
On day 7, 100 ml fresh medium was substituted, and peptide
Mage-3A1 or PB1 (1 mg/ml final) and IL-2 (10 U/ml) was
added. On day 12, each microwell was divided into three equal
samples to test cytolytic activity in a standard 4-h 51Cr-release
assay on peptide-pulsed (10 mg/ml for 1 h at 378C) T2A1 cells,
nonpulsed T2A1 cells, and K562 target cells, respectively. All of
the assays were performed with an 80-fold excess of nonlabeled
K562 to block NK activity. Microwells were scored positive if
lysis of T2A1 targets with peptide minus lysis without peptide
was $12% and this specific lysis was greater than or equal to
twice the lysis of T2A1 targets without peptide plus six as de-
scribed (18). We aimed at testing 30 microwells of 104 CD81 T
cells. Therefore, 1/30 positive wells equals at least one CTLp in
3 3 105 (i.e., 30 wells at 104 CTLp per well) CD81 T cells (cor-
responding to z3 3 106 PBMCs).
DTH. DTH to Mage-3A1 peptide was assessed by intra-
dermal injection at two sites of each 3 3 105 Mage-3A1 peptide–
loaded DC in 0.1 ml PBS. Negative controls were nonpulsed
autologous DCs in 0.1 ml PBS and 0.1 ml PBS. DTH to seven
common recall antigens (Multitest Merieux) including TT and
tuberculin was performed on visits 1, 5, and 8 (Table II).
Assessment and Analysis of Tumor Tissue
For recruitment into the study, Mage-3 gene expression in at
least one metastatic deposit had to be demonstrated by RT-PCR
as described (14). Accessible superficial skin metastases were re-
moved whenever possible after the vaccinations and subjected to
Mage-3 RT-PCR as well as routine histology and immunohis-
tology (to characterize cellular infiltrates).
Statistical Analysis
For analysis of the immune response, pre- and postimmuniza-
tion values were compared by paired t test after logarithmic trans-
formation of the data. Significance was set at P , 0.05.1672 Dendritic Cell Vaccination of Stage IV Melanoma Patients
Results
Patient Characteristics
All 13 patients were HLA-A11, had proven Mage-3
mRNA expression in at least one excised metastasis, and
suffered from advanced stage IV melanoma, i.e., distant
metastases that were progressive despite chemotherapy and,
in some cases, chemoimmunotherapy (Table I). We offered
DCs to all patients who fulfilled the inclusion and exclusion
criteria, i.e., we did not select for subsets of patients. Two
patients (numbers 01 and 03) succumbed to melanoma af-
ter two and three vaccinations, respectively. 11 patients re-
ceived all five planned DC vaccinations in 14-d intervals
(Table II) and were thus fully evaluable.
Quality of the Vaccine
All vaccine preparations were highly enriched in mature
DCs. More than 95% of the cells were large and veiled in
appearance, expressed a characteristic phenotype by flow
cytometry (HLA-DR111CD86111CD401CD251CD142),
and acted as strong stimulators of an MLR at DC/T cell ra-
tios of #1:300 (13). Most (mean 80%) expressed the CD83
mature DC marker (19). These features were stable upon
removal of cytokines and culture for one to two more days
(13). The DCs were pulsed with Mage-3A1 peptide as a tu-
mor antigen and TT or tuberculin as a recall antigen. The
latter were internal controls for immunization and possibly
provided help for CTL responses (20).
Toxicity
No major (above grade II) toxicity or severe side effects
were observed in any patient, including the two patients
who were not fully evaluable. We noticed, however, local
reactions (erythema, induration, pruritus) at the intracuta-
Table I. Patients’ Characteristics, Status before DC Vaccination, and Response to DC Vaccination
Treatment centers: three patients (04, 08, and 12) were treated in Wuerzburg, two in Mainz (patients 10 and 13), and the others in Erlangen.
Pretreatment therapy: PCI, polychemoimmuno. Preceding excisions and radiotherapies are not listed.
Metastases at study entry: the number and diameter of the largest metastases present at study entry are listed (number/diameter in millimeters).
m, multiple (.3 metastases).
Survival: (since onset of stage IV and as of 5 August 1999) is listed as months since onset stage IV until study entry 1 number of months since study
entry. †Patient deceased.
*CNS metastases were regressing at study entry after gamma knife treatment.
&Developed (in part) after study entry.
8Determined by autopsy.
“Sudden death from bleeding into CNS metastasis on visit 8.
#The regressions of lung metastases in patients 06 and 07 were documented at a staging 3 mo after visit 8.
mediast., mediastinum; pancr., pancreas.1673 Thurner et al.
neous vaccination sites that increased with the number of
vaccinations. In 9/11 patients, strong DTH reactions (in-
duration .10 mm in diameter) were noted to DCs carry-
ing a recall antigen (Fig. 1). Elevation of body temperature
(grade I and II fever) was observed in most (9/11) patients
and was also related to pulsing DCs with recall antigen.
The most striking example was patient 02, who progres-
sively developed fever (up to 408C) upon successive vacci-
nations but did not show a rise in body temperature when
TT was omitted for the final (fifth) vaccination. We observed
slight lymph node enlargement, clinically in 63% and by
sonography in 83% of patients, after the intracutaneous DC
injections. Interestingly, these were delayed, being inappar-
ent during the 2 d of monitoring after vaccinations but de-
tected when patients were investigated again the day before
the next vaccination (Table II).
Immunological Responses
Boosting of Recall Antigen-specific Immunity. PBMCs that
had been frozen before vaccination and 14 d after vaccina-
tion 5 were thawed and assayed together, as specified in the
protocol (Table II). In most patients, a significant boost of
antigen-specific immunity developed to TT (and tubercu-
lin in patient 10) (P , 0.004; Fig. 2). Supernatants from the
proliferative assays contained large amounts of IFN-g (mean
1,679 pg/ml, range 846–4,325) but little IL-4 (IFN-g/IL-4,
317:1). In five patients, we studied the kinetics of the immune
response to TT by IFN-g ELISPOT analysis. We found an
increase after the intracutaneous vaccinations (P , 0.02)
but a peculiar decrease after the intravenous vaccinations (P ,
0.008; Fig. 3). Thus, comparing recall immunity before and
after all five vaccinations (Fig. 2) as prespecified in the protocol
(Table II) obviously underestimated the extent of boosting.
Table II. Study Design
X, prespecified in the protocol as obligatory; x, optional.
Figure 1. Local reactions to DCs carrying Mage-3A1 peptide and TT
at the intradermal and subcutaneous vaccination sites in patient 09 (24 h
after vaccination 2; top panel) and 02 (48 h after vaccination 3; bottom
panel). Erythema at the 10 intradermal (left) and 2 subcutaneous (right)
vaccination sites was followed by induration .10 mm in diameter (with
secondary purpura in patient 02). These local reactions represent strong
DTH reactions to DCs carrying TT, as such strong reactions did not oc-
cur in response to unpulsed DCs or DCs pulsed with Mage-3A1 peptide
alone in DTH tests I–III (Table II; reactions not shown).1674 Dendritic Cell Vaccination of Stage IV Melanoma Patients
Expansion of Mage-3A1–specific CTLp. Aliquots of
PBMCs, frozen before the first and after the third and fifth
vaccinations, were thawed at the same time (Table II) and
subjected to a semiquantitative recall assay for CTLp (refer-
ence 17; Fig. 4). Before vaccination, CTLp frequencies
were low or undetectable. In 8/11 patients, we found a sig-
nificant expansion of Mage-3A1–specific CTLp as indicated
by the increase (mean, eightfold; P , 0.008) of positive
microcultures in the multiple microculture procedure em-
ployed for the semiquantitative assessment of CTLp (17).
Interestingly, in six patients, the CTLp frequencies were
maximal after the three intracutaneous vaccinations (P ,
0.0013) but then decreased after the two additional intrave-
nous vaccinations in all but one of these patients (P , 0.026).
Only in 1/11 patients did we observe an increase of CTLp
to an irrelevant PB1 influenza peptide that served as a spec-
ificity control (not shown).
ELISPOT Analysis for IFN-g–releasing, Mage-3A1–specific
T Cells. We also tried to detect Mage-3A1–specific CTL
effectors in uncultured fresh, nonfrozen PBMCs by per-
forming ELISPOT analyses at 14-d intervals on all patients.
A significant increase of Mage-3A1–reactive IFN-g spot–
forming cells was apparent only in patients 07 and 09 after
the first and second vaccinations, respectively, but the fre-
quency of Mage-3A1–specific effectors was very high
(z5,000 and 10,500/107 CD81 T cells; not shown).
DTH Test to Mage-3A1 Peptide–loaded DCs. Tests of DTH
to Mage-3A1 peptide–loaded DCs yielded erythema and/or
induration (.5 mm diameter) in 7/11 patients (not shown).
The results were, however, equivocal due to the frequently
observed background to nonpulsed DCs (up to 10 mm in
diameter) and the variability from test site to test site.
Clinical Responses
At the end of the trial, i.e., z2 wk after the fifth vaccina-
tion (Table II), we observed temporary growth cessation of
some individual metastases, but more intriguingly, in 6/11
patients, complete regression of individual metastases in
skin, lymph nodes, lung, and liver (Table I and Fig. 5).
Resolution of skin metastases was found in three patients
(Table I, patients 06, 07, and 08) and in two of them (06
and 07), it was preceded by local pain, itching, and slight
erythema. The six regressing skin lesions of patients 06 and
07 (Table I) were also excised and examined by immuno-
histology. Clusters of CD81 T cells were seen around and
in the tumor, the latter often necrotic, suggesting an im-
mune attack (Fig. 6).
In patients 06 and 08, the metastases excised at study
entry (four and two, respectively) proved to be Mage-3
mRNA1. However, all of the samples removed at the end
(two and six, respectively) were Mage-3 mRNA2, suggest-
ing immunoselection for antigen-negative tumor cells. Re-
markably, significant infiltration of CD81 T cells was not
found in any of these lesions.
Discussion
In deciding on the source of DCs for this phase I trial,
we selected mature, monocyte-derived DCs for the follow-
Figure 2. Recall antigen–specific immunity (tuberculin in patient 10;
TT in all others) as assayed by antigen-specific proliferation. The cpm val-
ues determined after therapy (14 d after vaccination 5) are shown as multi-
ples of pretherapy cpm values. Absolute cpm (cpm with recall antigen minus
cpm without antigen) after therapy was 68,917 in patient 02, 85,225 in pa-
tient 04, 16,759 in patient 05, 7,913 in patient 06, 16,367 in patient 07,
107,923 in patient 09, 22,790 in patient 10, 4,507 in patient 12, and 1,831
in patient 13 (SEM for all measurements was ,20%). Patients 08 and 11
could not be evaluated due to shortage of cells after therapy.
Figure 3. Kinetic analysis of immunity to recall antigens
as assessed by TT-specific IFN-g ELISPOT (SEM for all
measurements was ,20%). Blood was drawn (see Table II,
Study Design) before the first DC vaccination and then ev-
ery 14 d just before administration of the next DC vacci-
nation (e.g., pre Vacc # 2 means immediately before vacci-
nation 2, i.e., 14 d after vaccination 1), and finally after
therapy. Time points at which vaccinations were not per-
formed lack bars. Note the increase after the intracutane-
ous vaccinations and the decline upon the two vaccina-
tions after intravenous ones. Patient 10, who received
tuberculin-pulsed DCs, exhibited no significant change in
the TT-specific IFN-g ELISPOT as expected.1675 Thurner et al.
ing reasons. Monocyte-derived DCs currently represent
the most homogenous and potent DC populations, with
several defining criteria and quality controls (12, 13, 21).
The method for generating production of these DCs is
very reproducible and allows the cryopreservation of large
numbers of cells at an identical stage of development (12,
13). Furthermore, these DCs can be produced in the ab-
sence of potentially hazardous FCS (12, 13, 21). FCS expo-
sure also leads to large syngeneic T cell responses in cul-
ture, so their clinical use (11) might produce nonspecific
immunostimulatory effects. Unlike other investigators (9–11),
we chose to use mature rather than immature DCs for our
first melanoma trial. The DCs that have been used with ef-
ficacy in animal experiments were primarily mature (3, 8).
Mature DCs are much more potent in inducing CTL and
Th1 responses in vitro (reference 22 and Jonuleit, H., A.
Gieseke, A. Kandemir, L. Paragnik, J. Knop, and A.H.
Enk, manuscript in preparation), and the DCs are also resis-
tant to the immunosuppressive effects of IL-10 (23) that
can be produced by tumors (24–26). Mature DCs also
display an extended half-life of antigen-presenting MHC
class I (26a) and class II molecules (27). Finally, mature
DCs have a high migratory activity (21) and express CCR7
(28), a receptor for chemokines produced constitutively in
lymphoid tissues (28). Mature DCs, as used in this cancer
therapy trial, have recently also been shown to rapidly gen-
erate broad T cell immunity in healthy subjects (28).
Mature DCs were loaded with only one melanoma pep-
tide, Mage-3A1, to avoid uncertainties regarding loading of
DCs with multiple peptides (11) of varying affinity and off
rate. Successful loading was verified with a Mage-3A1–spe-
cific CTL clone and ELISPOT analysis (not shown). The
Mage-3A1 peptide (15) was selected for several reasons. It is
essentially tumor specific (2) and expressed in tumors other
than melanoma (2), and the Mage-3A1 epitope is likely a re-
jection antigen (14). Moreover, the Mage-3A1 CTLp fre-
quency is exceedingly low in noncancer patients (reference
18; 0.4–3 per 107 CD81 T cells) as well as in cancer patients,
even after peptide vaccination (14). Thus, any induction or
boost of Mage-3A1 CD81 T cell responses would indicate a
significant superiority in the adjuvant capacities of DCs.
DTH assays with peptide-pulsed DCs were carried out
as described by Nestle et al. (11) to detect Mage-3A1 im-
munity (not shown). However, we did not detect un-
equivocal DTH. This was due to the frequently observed
background to nonpulsed DCs (possibly due to cytokine
production by DCs) and the noteworthy variability from
test site to test site. As Mage-3A1–specific T cells are CD81
Figure 4. Mage-3A1 CTLp frequency analysis as as-
sessed by semiquantitative recall assay. The y-axis and the
numbers above the bars indicate the percentage of positive
wells found before vaccination 1, before vaccination 4 (14 d
after vaccination 3), and after therapy (usually 14 d after
vaccination 5).
Figure 5. Regression (arrows) of a globular (13
mm in diameter) lung metastasis in patient 07 that
was then no longer detectable in serial 6-mm-thick
computed tomography scans.1676 Dendritic Cell Vaccination of Stage IV Melanoma Patients
T cells and DTH assays typically detect primed CD41 T
cells, we suspect that DTH to MHC class I peptide–pulsed
DCs may also for this reason prove not to be a sensitive or
reliable way to monitor specific CD81 T cell–mediated im-
munity.
In contrast, we found sizable expansions of Mage-3A1–
specific CTL precursors in PBMCs from a majority (8/11)
of patients (P , 0.008; Fig. 4). This is an important proof
of the principle of DC-based immunization, and it is also
significant from the point of view that tumors can induce
tolerance or anergy. It is very promising that CTLp expan-
sions can be induced in far advanced and heavily pretreated
stage IV melanoma patients. However, active Mage-3A1–
specific effectors were generally not observed in ELISPOT
assays, except for in two patients with high frequencies
(.5,000/107 CD81 T cells). Perhaps active CD81 effectors
were rapidly sequestered in the numerous metastases, as
suggested by the biopsy studies illustrated in Fig. 6. An al-
ternative explanation is that looking for effectors in periph-
eral blood 14 d after a preceding vaccination might simply
be too late.
Interestingly, in six patients, CTLp had increased to their
highest levels after the three intracutaneous vaccinations
(P , 0.0013) and then decreased (P , 0.026) with subse-
quent intravenous immunizations (Fig. 4). The decrease in
CTLp might be due to emigration of activated Mage-3–
reactive CTLs into tissues, tolerance induction, or clonal
exhaustion via the intravenous route. We also observed de-
creased responses to recall antigens in the five patients that
we studied before and after intravenous vaccination (Fig. 3).
The effect of the intravenous route requires additional
study, as it may be counterproductive. In contrast, our re-
sults clearly demonstrate that the intracutaneous route is ef-
fective, so that the less practical intranodal injection propa-
gated by other investigators (11) does not seem essential. It
will, however, be necessary to compare subcutaneous and
intradermal routes to find out if one is superior.
We found regression of individual metastases in 6/11 pa-
tients when patients were staged 14 d after the fifth vacci-
nation (Table I). This percentage of responses was unex-
pected in far advanced stage IV melanoma patients who
were all progressive despite standard chemotherapy and
even chemoimmunotherapy. In the study by Nestle et al.
(11), chemotherapy was only given to 4/16 melanoma pa-
tients, and objective tumor responses were observed in
5/16. Therefore, we attribute the regressions to DC-medi-
ated induction of Mage-3A1–specific CTLs. This interpre-
tation is supported by the heavy infiltration with CD81 T
cells of regressing but not nonregressing (skin) metastases.
The observation that all of the metastases in patients 06 and
08 that were excised at the end of the study were Mage-3
mRNA2 (whereas those removed at the onset were uni-
formly positive) suggests immune escape of and selection
for Mage-3 antigen–negative tumors. Immune escape
might also have been responsible for the lack of tumor re-
sponse in those nonresponders that had mounted a Mage-
3A1–specific CTL response.
After the end of the trial, surviving patients received fur-
ther vaccinations with DCs and several tumor peptides
(Mage-1, tyrosinase, and Mage-3) that were no longer part
of the protocol. It is encouraging that 5/11 patients are still
alive (Table I) 9–17 mo after study entry, as the expected
median survival in patients progressive after chemo(im-
muno)therapy is only 4 mo (29, 30). One of the initial re-
sponders (patient 06) has recently experienced a complete
response and has now been disease free for 2 mo. It is inter-
esting that Marchand et al. (14) have also observed that re-
gressions, once they have started, proceed slowly and may
take months to complete.
In conclusion, the use of a defined DC vaccine com-
bined with detailed immunomonitoring provides proof that
vaccination with mature DCs expands tumor-specific T
cells in advanced melanoma patients. In addition, we have
found some evidence for the direct interaction between
Figure 6. Regressing subcutaneous metastases in patient 06 display a CD81 lymphocytic infiltrate (alkaline phosphatase/antialkaline phosphatase immunohis-
tochemical staining with anti-CD8 mAb) that surrounds (A) and infiltrates (B) the tumor. Areas of damaged (B, w) and necrotic (C, w) melanoma cells are ob-
vious in the vicinity of the CD81 T cell infiltrate. The metastasis expressed Mage-3, as demonstrated by RT-PCR (data not shown). Magnifications: A, 100; B,
250; C, 160.1677 Thurner et al.
CD81 CTLs and tumor cells as well as for escape of antigen-
negative metastases. We are convinced that DC-mediated
immunization can be intensified further to reveal the pres-
ence of expanded populations of effector cells. Efficacy might
be increased at the level of the DC, e.g., by optimizing
variables such as DC maturational state, route, dose, and
schedule or by improving the short life span of DCs in vivo
(31, 32); at the level of the T cell, e.g., by providing mela-
noma-specific CD41 T cell help (33, 34) or IL-2 (35); and
by treating patients earlier in their disease course.
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